


12

11

# At a Glance


**Profile** HBM BioVentures invests in the health-care sector. The Company holds and manages an international portfolio of some twenty five promising companies in the biotechnology/ human medicine, medical technology and diagnostics sectors. Many of these companies have their lead products already available on the market, or at an advanced stage of development. The focus of investment is on follow-on

financing for existing portfolio companies. These portfolio companies are closely tracked and actively guided on their strategic directions. This is what makes HBM BioVentures an interesting alternative to investing in big pharma and biotech companies. HBM BioVentures has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN).




## Allocation of assets

Mainly invested in private companies with high value-creation potential.




## Currency allocation of net assets

Emphasis on US dollar investments.



## Development phase of portfolio companies<sup>1)</sup>

Largely invested in profitable companies or in companies with products available on the market.



## Therapeutic area of the lead products of portfolio companies<sup>1)</sup>

Broadly diversified areas of activity.

1) Total investments as at 31.12.2011: CHF 405 million.

# Key Figures, Performance and the ten largest Investments

Key Figures		31.12.2011	31.3.2011	31.3.2010	31.3.2009	31.3.2008
<b>Net assets</b>	CHF million	<b>508.6</b>	<b>589.2</b>	<b>666.1</b>	<b>618.9</b>	<b>948.3</b>
Investments in private companies		293.5	367.6	532.6	594.5	685.0
Investments in public companies		111.9	83.4	100.3	132.0	311.7
Cash and cash equivalents		69.9	155.8	129.1	65.6	86.8
<b>Net cash flow from investing activities</b>	CHF million	<b>-14.0</b>	<b>148.9</b>	<b>186.9</b>	<b>27.9</b>	<b>83.5</b>
<b>Net result for the period/for the year</b>	CHF million	<b>-57.4</b>	<b>-56.4</b>	<b>66.0</b>	<b>-312.9</b>	<b>-222.3</b>
Basic earnings per share	CHF	-6.09	-5.73	6.39	-28.98	-19.90
Net asset value (NAV) per share	CHF	56.00	61.15	65.85	58.80	86.60
Share price	CHF	39.95	44.60	49.50	22.00	68.95
<b>Discount</b>		<b>-28.7%</b>	<b>-27.1%</b>	<b>-24.8%</b>	<b>-62.6%</b>	<b>-20.4%</b>
Shares issued	Registered shares (m)	9.8	10.2	10.7	11.3	11.3
Shares outstanding	Registered shares (m)	9.1	9.6	10.1	10.5	11.0

Performance	Quarter	Current financial year	Calendar year	Since start of business (12.7.2001)
<b>HBM BioVentures Ltd</b>				
Net asset value (NAV)	-0.6%	-8.4%	-3.6%	-44.6%
Registered share HBMN	-3.3%	-10.4%	-6.0%	-60.4%
<b>Relevant market indices in Swiss francs</b>				
Nasdaq Biotech Index (NBI)	15.6%	6.4%	12.2%	-33.7%
MSCI World Pharma Index	12.3%	9.8%	9.0%	-47.1%

The 10 largest investments as at 31.12.2011 <sup>1)</sup>		Fair value (CHF 000)	As % of net assets
<b>Private companies</b>			
Cathay Industrial Biotech		26,267	5.2%
PTC Therapeutics		23,736	4.7%
Lux Biosciences		20,015	3.9%
ChemoCentryx		17,318	3.4%
Nabriva Therapeutics		15,715	3.1%
Ophotech		15,439	3.0%
Interventional Spine		14,186	2.8%
Probiobdrug		9,240	1.8%
<b>Public companies</b>			
Basilea Pharmaceutica <sup>P)</sup>		68,374	13.4%
Pacira Pharmaceuticals <sup>P)</sup>		27,957	5.5%

P) Position originating from the private companies portfolio.

1) Excluding venture capital funds.

## Dear Shareholders

HBM BioVentures' net asset value (NAV) per share decreased by 0.6% to CHF 56.00 during the reporting period. The decline in the valuation of the largest public investments was offset by the rise in the US dollar against the Swiss franc. The share price fell by 3.3%, more than the NAV, to stand at CHF 39.95 at the end of December.

**“Potentially value-enhancing events are expected for both Basilea and Pacira, the largest public holdings.”**

The outstanding CHF 30 million bond was repaid in full in mid-December. HBM BioVentures has a sound balance sheet, with an equity ratio of 99% and cash and cash equivalents of CHF 70 million, or 14% of assets. 57% of assets is invested in private companies (42% directly and 15% indirectly via third-party funds), and 22% is invested in public companies. Some 7% is accounted for by risk-weighted and discounted claims to performance-related milestone payments from trade sales, which could potentially be much higher if the companies in question perform well.

Around 57% of net assets is invested in US dollars, while 12% is invested in euros. Foreign exchange risks are not hedged at present.

## Public companies

At the end of October, Pacira Pharmaceuticals received approval from the US Food and Drug Administration (FDA) for Exparel™, a local injectable agent to alleviate post-surgical pain which provides relief for up to 72 hours. Despite achieving this important milestone, Pacira's share price fell by 12.8% during the quarter under review. Marketing for Exparel™ will begin in Q2 2012 and should lead to an increase in the company's value.

The share price of Basilea Pharmaceutica, the largest investment in the portfolio, fell by 8.2% during the reporting period. HBM BioVentures took the opportunity presented by Basilea's persistently low market valuation to further increase its position in the fourth calendar quarter of 2011. As at the end of December, HBM BioVentures held just under 20% of the company. Its position as Basilea's largest investor allows HBM BioVentures to present its views on the company's strategic orientation to its board of directors and management. The Extraordinary Shareholders' Meeting, which was held at the end of November at the request of HBM BioVentures, appointed three new members to the Basilea board of directors.

In early 2012, Basilea successfully concluded the audits of 26 study centres, and the associated data analyses, from two clinical phase III trials of the Ceftobiprol antibiotic in patients with severe pneumonia. On the strength of these trials, Basilea intends to apply for approval for Ceftobiprol for the European market in the second half of 2012. The next steps concerning the submission of an application for regulatory approval for the US market will be determined following discussions with the FDA.

Basilea is also expecting data from US phase III trials for its Toctino® product in Q1 2012. Toctino® is already marketed in Europe. Positive study results would provide the basis for an application to have the medication approved for the treatment of hand eczema in the US market

### Private companies

In the private company portfolio, PTC Therapeutics concluded a licensing agreement with Roche for a pre-clinical development programme for the treatment of spinal muscular atrophy (SMA). PTC received an upfront payment of USD 30 million, and is entitled to additional milestone payments of up to USD 460 million, as well as double-digit percentage royalties on potential sales. Although this licensing agreement does not impact directly on the valuation of HBM BioVentures' investment in PTC, it secures the company's financing for the coming months.

Probiodrug secured financing from a new investor shortly before the end of the year. The value of the investment was increased by 20% as a result.

Erwin Troxler took over as Chief Financial Officer (CFO) of HBM BioVentures with effect from 1 November 2011. Dr Joachim Rudolf, who had held the position since HBM BioVentures was founded in 2001, left the Company at his own instigation to become CFO of Cathay Industrial Biotech, the largest private company in the HBM BioVentures portfolio.

### Outlook

The expected announcements of study results, new promising partnerships and the commercial launch of Exparel™ are all potentially value-enhancing events for both Basilea and Pacira, the largest public holdings. We also anticipate developments (study results, IPOs or trade sales) at a variety of private companies over the next 12 months that will have a bearing on their value.

Our team provides portfolio companies with hands-on support for their sales and IPOs, and thus plays an active part in value growth for the future. It remains to be seen whether or not the forthcoming study results will confirm the findings of earlier work.



Dr Andreas Wicki  
CEO



Erwin Troxler  
CFO

# Consolidated Interim Financial Statements

## Consolidated balance sheet

4

	Notes	31.12.2011	31.3.2011
<b>Assets (CHF 000)</b>			
Current assets			
Cash and cash equivalents		69,857	155,789
Financial instruments		208	633
Receivables		1,245	7,246
Inventories		513	554
<b>Total current assets</b>		<b>71,823</b>	<b>164,222</b>
Non-current assets			
Investments	(2)	405,420	450,953
Other financial assets	(3)	33,835	7,955
Property, plant and equipment		262	187
Intangible assets		5,261	5,010
<b>Total non-current assets</b>		<b>444,778</b>	<b>464,105</b>
<b>Total assets</b>		<b>516,601</b>	<b>628,327</b>
<b>Liabilities (CHF 000)</b>			
Short-term liabilities			
Financial instruments		0	353
Short-term financial liabilities	(4)	0	36,166
Other short-term liabilities		1,470	2,580
<b>Total short-term liabilities</b>		<b>1,470</b>	<b>39,099</b>
Long-term liabilities			
Long-term financial liabilities	(4)	6,482	0
<b>Total long-term liabilities</b>		<b>6,482</b>	<b>0</b>
Shareholders' equity			
Share capital	(5)	588,000	612,000
Treasury shares	(5)	-31,867	-26,257
Capital reserve		375,480	369,019
Currency translation differences		75	89
Accumulated loss		-423,039	-365,623
<b>Total shareholders' equity</b>		<b>508,649</b>	<b>589,228</b>
<b>Total liabilities and shareholders' equity</b>		<b>516,601</b>	<b>628,327</b>
Number of outstanding shares (in 000)		9,083	9,635
Net asset value (NAV) per share (CHF)		56.00	61.15

# Consolidated Interim Financial Statements

## Consolidated statement of income for the period 1 April to 31 December

	Notes	Quarter ended 31.12.2011	Quarter ended 31.12.2010	9-month period ended 31.12.2011	9-month period ended 31.12.2010
Result from investment activities (CHF 000)					
Gains on investments	(2)	11,130	9,843	49,131	17,221
Losses on investments	(2)	-15,455	-36,884	-84,702	-94,574
Result from currency hedging transactions		-380	0	-9,961	11,540
Gains from other financial instruments		0	0	33	0
Losses from other financial instruments		-37	0	0	0
Gains on other financial assets		1,230	191	2,465	1,590
Losses on other financial assets		0	-834	-834	-3,936
<b>Gross result from investment activities</b>		<b>-3,512</b>	<b>-27,684</b>	<b>-43,868</b>	<b>-68,159</b>
Result from product sales					
Revenues from product sales		45	30	118	118
Costs of products sold		-41	136	-111	56
<b>Gross result from product sales</b>		<b>4</b>	<b>166</b>	<b>7</b>	<b>174</b>
<b>Gross result</b>		<b>-3,508</b>	<b>-27,518</b>	<b>-43,861</b>	<b>-67,985</b>
Management fee		-1,990	-2,403	-6,373	-7,867
Personnel expenses		-744	-704	-2,020	-2,309
Other operating expenses		-775	-1,275	-2,788	-3,552
Depreciation and amortisation		-12	-15	-37	-75
<b>Operating result before interest and taxes</b>		<b>-7,029</b>	<b>-31,915</b>	<b>-55,079</b>	<b>-81,788</b>
Financial income		43	8	136	24
Financial expenses		-736	-954	-2,472	-3,111
<b>Result before taxes</b>		<b>-7,722</b>	<b>-32,861</b>	<b>-57,415</b>	<b>-84,875</b>
Income taxes		0	0	-1	0
<b>Net result for the period</b>		<b>-7,722</b>	<b>-32,861</b>	<b>-57,416</b>	<b>-84,875</b>
Number of outstanding shares, time-weighted (in 000)		9,246	9,885	9,430	9,958
Basic earnings per share (CHF)		-0.84	-3.32	-6.09	-8.52

As the Company does not have options or similar instruments outstanding, diluted earnings per share are identical to basic earnings per share.

## Consolidated statement of comprehensive income for the period 1 April to 31 December

	Quarter ended 31.12.2011	Quarter ended 31.12.2010	9-month period ended 31.12.2011	9-month period ended 31.12.2010
(CHF 000)				
<b>Net result for the period</b>	<b>-7,722</b>	<b>-32,861</b>	<b>-57,416</b>	<b>-84,875</b>
Contribution to operating result reported in shareholders' equity				
Change owing to currency translation differences	-26	319	-14	767
<b>Total comprehensive result</b>	<b>-7,748</b>	<b>-32,542</b>	<b>-57,430</b>	<b>-84,108</b>

# Consolidated Interim Financial Statements

## Consolidated statement of cash flows

### for the period 1 April to 31 December

6

(CHF 000)	9-month period ended 31.12.2011	9-month period ended 31.12.2010
Revenues from product sales received	104	115
Costs of products sold paid	-35	-18
Management fee paid	-6,373	-7,867
Other expenses paid (personnel and other operating expenses)	-4,746	-5,385
<b>Net cash flow from operating activities</b>	<b>-11,050</b>	<b>-13,155</b>
Interest payments received	136	19
Purchase of investments	-96,401	-47,059
Sale of investments	86,938	65,411
Payments received from escrow amounts and milestones	5,428	6,393
Net cash flow from financial instruments to hedge currency risks	-10,314	11,540
Sale of other financial instruments	458	0
Purchase of property, plant and equipment and intangibles	-269	-102
<b>Net cash flow from investing activities</b>	<b>-14,024</b>	<b>36,202</b>
Interest paid on financial liabilities	-3,153	-6,062
Redemption of financial liabilities	-30,000	-77,661
Purchase of treasury shares	-30,314	-20,908
Sale of treasury shares	3,044	3,697
<b>Net cash flow from financing activities</b>	<b>-60,423</b>	<b>-100,934</b>
<b>Currency translation differences</b>	<b>-435</b>	<b>-414</b>
<b>Net change in cash and cash equivalents</b>	<b>-85,932</b>	<b>-78,301</b>
Cash and cash equivalents at beginning of period	155,789	129,084
Cash and cash equivalents at end of period	69,857	50,783



# Consolidated Interim Financial Statements

## Consolidated statement of changes in equity

	Share capital	Treasury shares	Capital reserve	Currency translations differences	Accumulated loss	Total shareholders' equity
<i>(CHF 000)</i>						
<b>Balance as at 31 March 2010</b>	<b>642,000</b>	<b>-30,358</b>	<b>363,900</b>	<b>-153</b>	<b>-309,241</b>	<b>666,148</b>
Net result for the period					-84,875	-84,875
Currency translation differences				767		767
<b>Total comprehensive result</b>						<b>-84,108</b>
Purchase of treasury shares		-20,908				-20,908
Sale of treasury shares		4,922	-1,225			3,697
Capital reduction (3.9.2010)	-30,000	23,617	6,383			0
<b>Balance as at 31 December 2010</b>	<b>612,000</b>	<b>-22,727</b>	<b>369,058</b>	<b>614</b>	<b>-394,116</b>	<b>564,829</b>
Net result for the period					28,493	28,493
Currency translation differences				-525		-525
<b>Total comprehensive result</b>						<b>27,968</b>
Purchase of treasury shares		-5,551				-5,551
Sale of treasury shares		2,021	-39			1,982
<b>Balance as at 31 March 2011</b>	<b>612,000</b>	<b>-26,257</b>	<b>369,019</b>	<b>89</b>	<b>-365,623</b>	<b>589,228</b>
Net result for the period					-57,416	-57,416
Currency translation differences				-14		-14
<b>Total comprehensive result</b>						<b>-57,430</b>
Purchase of treasury shares		-30,314				-30,314
Sale of treasury shares		7,310	-145			7,165
Capital reduction (2.9.2011)	-24,000	17,394	6,606			0
<b>Balance as at 31 December 2011</b>	<b>588,000</b>	<b>-31,867</b>	<b>375,480</b>	<b>75</b>	<b>-423,039</b>	<b>508,649</b>

# Consolidated Interim Financial Statements

## Notes

8

### 1. Summary of significant accounting policies

The consolidated interim financial statements have been prepared in accordance with the International Financial Reporting Standards (IFRS) IAS 34 on Interim Financial Reporting and the provisions of the SIX Swiss Exchange Additional Rules on the Listing of Investment Companies. These interim financial statements should be read in conjunction with the consolidated financial statements for the financial year ended 31 March 2011, as they provide an update to the latest full financial report. In preparing the interim financial statements, the same accounting principles and methods of computation have been applied as in the preparation of the annual financial statements.

A summary of the new and revised IFRS/IAS standards and interpretations effective in the year under review is provided on page 51 of the Consolidated Financial Statements of the 2010/2011 Annual Report. The use of these standards had no impact on the financial condition or the earnings situation of the Company, or on its accounting principles.

The following conversion rates were used in the preparation of the financial statements:

(CHF)	31.12.2011	31.3.2011
DKK	0.1636	0.1745
EUR	1.2159	1.3011
GBP	1.4581	1.4730
SEK	0.1362	0.1453
USD	0.9381	0.9190

### 2. Investments

Investments developed as follows during the reporting period:

(CHF 000)	Private companies	Venture capital funds	Public companies	Total investments
<b>Fair value as at 31 March 2011</b>	<b>267,450</b>	<b>100,123</b>	<b>83,380</b>	<b>450,953</b>
Purchases	22,493	4,536	72,990	100,019
Sales	-76,419	-26,033	-7,529	-109,981
Realised gains	29,812	13,980	825	44,617
Realised losses	-116,859	-612	-695	-118,166
Changes in unrealised gains	128,020	3,668	6,475	138,163
Changes in unrealised losses	-36,828	-19,769	-43,588	-100,185
<b>Fair value as at 31 December 2011</b>	<b>217,669</b>	<b>75,893</b>	<b>111,858</b>	<b>405,420</b>

Details on investments can be found on pages 11 and 12.

### 3. Other financial assets

The sale of a number of investment positions has given HBM BioVentures contractual claims to further purchase price payments that are contingent on the achievement of defined targets. These claims

are carried in the annual financial statements at a risk-weighted value, discounted over time (discount rate of 8-12 percent). The following summary shows the value carried in the balance sheet compared with the potential cash flows:

(CHF million)	Book value as at 31/12/2011	Range of possible cash flows, minimum	Range of possible cash flows, maximum	Expected period of payment
ESBATEch	7.5	0.0	55.9	2014–2018
Mpex <sup>1)</sup>	10.4	4.7	>38.0	2012–2029
mtm laboratories	18.8	5.8	31.6	2013–2016
Other companies	4.1	0.0	13.9	2012–2019
<b>Total</b>	<b>40.8</b>	<b>10.5</b>	<b>&gt; 139.4</b>	

1) There is no ceiling on potential cash flows. The amount shown here is calculated on the basis of a cautious sales estimate.

Of the total book value as at 31 December 2011, CHF 33.7 million is carried under other financial assets (claims from investments held by HBM BioVentures directly). A further CHF 7.1 million is reported under investments, other private companies (claims from investments held indirectly via HBM BioCapital (EUR) L.P.).

If the companies concerned are successful, these contractual claims could result in future payments which are many times the reported book value.

#### ESBATEch

The company was acquired in September 2009 by Alcon Inc. The purchase price comprised an advance payment of USD 150 million, as well as a further USD 439 million in milestone payments that are tied to the achievement of clinical development targets. In addition to the advance, HBM BioVentures has to date received a small initial milestone payment. No further such payments are anticipated before 2014.

#### Mpex

The company was acquired in April 2011 by Axcen Pharma Inc. (now named Aptalis). Aptalis is paying the purchase price in cash – a guaranteed portion in tranches up to 2014, and the remainder as milestone payments contingent on market licensing and sales successes. HBM BioVentures will receive around USD 7 million in several tranches up to 2014. A further payment of approx. USD 8 million will fall due upon the registration and subsequent licensing of the Aeroquin™ antibiotic. HBM BioVentures

is also entitled to turnover-based payments on the basis of product sales up to 2029. These may correspond to several times the current book value of the investment.

#### mtm laboratories

The company was acquired in July 2011 by Roche. The purchase price for the company of EUR 190 million comprised an advance payment of EUR 130 million and EUR 60 million as performance-based milestone payments. HBM BioVentures has received 90% of the advance payment. The remaining 10% will be released 18 and 60 months after completion of the transaction. The performance-related milestone payment is expected in 2014/2015.

#### Other companies

“Other companies” relates primarily to contractual claims from the sale of the investment holdings in Asthmatx, Adnexus and Syntonix, which are tied to sales growth, advances in clinical development and product approvals.

#### 4. Financial liabilities

The following financial liabilities were outstanding within the HBM BioVentures Group as of the balance sheet date:

> Debtor: Tensys Medical Inc.

USD 6.9 million secured loan, including cumulated interest, interest rate 3.5% on the nominal value of USD 5 million, maturity 2 May 2015, convertible into 30% of outstanding shares of Tensys Medical Inc. The straight bond with nominal CHF 30 million was repaid as per 16 December 2011.

## 5. Equity capital

### 5.1 Share capital

As at the balance sheet date, the Company's share capital amounts to CHF 588 million, divided into 9,800,000 registered shares at a par value of CHF 60 each. The Ordinary Shareholders' Meeting of 24 June 2011 decided to reduce the Company's share capital by cancelling 400,000 treasury shares. The capital reduction was entered in the Commercial Register of the Canton of Zug on 2 September 2011.

### 5.2 Treasury shares

The Ordinary Shareholders' Meeting of 4 September 2009 authorised the Board of Directors to repurchase a maximum of 2,140,000 of the Company's own shares via a second trading line as part of a share buy-back programme lasting until 31 August 2012 at the latest and aimed at reducing capital ("Share buy-back programme 2009"). As part of this 2009 share buy-back programme, a total of 1,463,145 treasury shares were acquired, 500,000 of which were cancelled on 3 September 2010 and 400,000 on 2 September 2011 as part of the capital reduction. As at the balance sheet date of 31 December 2011, the Company held 563,145 of its own shares (31 March 2011: 349,311 own shares). In the 9-month period of the current financial year, a total of 613,834 of the Company's own shares were purchased via a second trading line at an average price of CHF 43.65.

Additionally, as at the balance sheet date of 31 December 2011, the HBM BioVentures (Cayman) Ltd. subsidiary holds 153,806 treasury shares (31 March 2011: 215,690 treasury shares), which have been purchased over the regular trading line. In the 9-month period until end of December 2011, a total of 80,479 treasury shares were purchased at an average price of CHF 43.74 per share (previous year: 127,531 treasury shares at CHF 43.12) and

142,363 treasury shares were sold at an average price of CHF 50.33 per share (previous year: 85,347 treasury shares at CHF 43.31) via the regular trading line. The number of shares sold in the 9-month period includes 73,144 own shares that were exchanged against a portfolio of private investments, in which HBM BioVentures already is invested. The exchange came at fixed valuations based on the net asset value as at 30 September 2011. The loss of CHF 0.1 million (previous year: loss of CHF 1.2 million) from trading in treasury shares, which is reported in shareholders' equity, is based on the proceeds of shares sold minus the pro-rata average acquisition price of all shares purchased over the regular trading line.

## 6. Investment commitments

	31.12.2011	31.3.2011
(CHF 000)		
HBM BioCapital (EUR) L.P.	2,520	3,612
Private companies	4,107	1,349
Venture capital funds	14,450	18,911
<b>Total investment commitments</b>	<b>21,077</b>	<b>23,872</b>

## 7. Management fees

The annual management fee to HBM Partners amounts to 1.2 % of the Company assets plus 0.3% of the market capitalisation of the Company. In the 9-month period until end of December 2011, HBM Partners was paid CHF 6.4 million (previous year: CHF 7.9 million).

## 8. Transactions with related parties

HBM BioVentures holds an investment in the Hatteras Venture Partners III venture capital fund, where Robert A. Ingram, Member of the Board of Directors, serves as General Partner. For details on the investment commitment, paid-in capital and valuation, please refer to the overview of venture capital funds on page 12.

## Investments

	Domicile	Investment currency (IC)	Amount disbursed as at 31.3.2011 (IC m)	Changes in the reporting period (IC m)	Amount disbursed as at 31.12.2011 (IC m)	Fair value as at 31.12.2011 (IC m)	Ownership as % of portfolio company	Fair value as at 31.12.2011 (CHF 000)	Fair value as at 31.3.2011 (CHF 000)
<b>Private companies</b>									
Cathay Industrial Biotech	China	USD	28.0		28.0	28.0	12.4%	26,267	25,732
PTC Therapeutics	USA	USD	24.2	1.1	25.3	25.3	10.2%	23,736	35,988
Lux Biosciences <sup>1)</sup>	USA	USD	19.2	2.1	21.3	21.3	15.0%	20,015	17,646
ChemoCentryx	USA	USD	12.3	1.3	13.7	18.5	8.0%	17,318	15,764
Nabriva Therapeutics <sup>1)</sup>	Austria	EUR	10.4	2.5	12.9	12.9	14.0%	15,715	13,569
Ophthotech	USA	USD	16.5		16.5	16.5	16.9%	15,439	15,125
Interventional Spine	USA	USD	14.6	1.9	16.5	15.1	30.7%	14,186	17,479
Probiodrug	Germany	EUR	13.7	0.7	14.3	7.6	10.1%	9,240	7,338
Medimpulse Holding	Switzerland	USD	4.4		4.4	8.3	20.7%	7,781	7,622
Ellipse Technologies <sup>2)</sup>	USA	USD	0.0	8.0	8.0	8.0	24.7%	7,508	0
Cylene Pharmaceuticals	USA	USD	12.2	0.7	12.9	7.9	10.1%	7,426	11,212
Enanta Pharmaceuticals	USA	USD	7.7		7.7	7.7	6.1%	7,221	7,074
Vivacta	UK	GBP	3.9	0.2	4.1	4.1	17.9%	5,922	5,683
Paratek Pharmaceuticals	USA	USD	5.7		5.7	5.0	3.1%	4,717	4,621
Cardiac Assist	USA	USD	4.2		4.2	4.2	9.1%	3,922	3,842
MiCardia <sup>1)</sup>	USA	USD	3.2	0.5	3.8	3.8	8.0%	3,523	2,964
Delenix Therapeutics <sup>1)</sup>	Switzerland	CHF	5.3		5.3	2.9	18.8%	2,871	2,871
Westmed Holding	USA	USD	5.5		5.5	2.7	12.4%	2,568	2,515
Nereus Pharmaceuticals <sup>1)</sup>	USA	USD	14.5	1.2	15.7	0.5	9.2%	423	7,957
mtm laboratories <sup>1)3)</sup>	Germany	EUR	24.3	-24.3	0.0	0.0	0.0%	0	36,612
Mpex Pharmaceuticals <sup>1)3)</sup>	USA	USD	13.4	-13.4	0.0	0.0	0.0%	0	9,526
Other investments								21,873	16,309
<b>Total private companies</b>								<b>217,669</b>	<b>267,450</b>

1) As explained in Note 3 of the annual financial statements, this investment was made partly or wholly through HBM BioCapital (EUR) L.P. HBM BioCapital's pro rata fees are reimbursed in full to HBM BioVentures so that fees are not levied twice.

2) HBM BioVentures holds an additional approx. 6.1% stake in the company indirectly via the MedFocus Fund since August 2005.

3) The investment was sold during the period under review.


	Domicile	Investment currency (IC)	Total commitment (IC m)	Payments in the reporting period (IC m)	Repayments in the reporting period (IC m)	Cumulative payments as at 31.12.2011 (IC m)	Cumulative repayments as at 31.12.2011 (IC m)	Fair value as at 31.12.2011 (IC m)	Fair value as at 31.12.2011 (CHF 000)	Fair value as at 31.3.2011 (CHF 000)
<b>Venture capital funds</b>										
Water Street Healthcare Partners	USA	USD	15.0	0.2		14.8	1.5	18.2	17,091	14,714
BioMedInvest I	Switzerland	CHF	26.0			26.0	7.8	16.9	16,873	19,085
MedFocus Fund II	USA	USD	16.0			16.0	0.0	12.5	11,727	13,033
Galen Partners V	USA	USD	10.0			5.4	0.0	6.3	5,864	4,389
Hatteras Venture Partners III	USA	USD	10.0	0.7		5.7	1.5	5.0	4,663	3,729
BioVeda China	China	USD	8.5		26.3	8.5	27.2	4.8	4,486	28,755
Symphony Capital Partners	USA	USD	15.0	0.1	0.5	14.7	7.4	4.6	4,306	4,883
BioMedInvest II	Switzerland	CHF	10.0	2.0		4.0	0.0	3.5	3,490	2,269
Nordic Biotech	Denmark	DKK	31.0			28.2	9.8	15.1	2,468	3,251
EMBL Technology Fund	Germany	EUR	2.1			2.1	0.0	1.7	2,088	2,020
BioVentures Investors II	USA	USD	3.0			3.0	0.5	1.1	1,009	993
Heidelberg Innovation BSV II	Germany	EUR	5.0		0.3	5.0	1.2	0.8	917	1,258
Skyline Venture Partners III	USA	USD	3.0		0.1	2.9	2.5	0.5	474	974
A.M. Pappas LifeScience Ventures II	USA	USD	3.0		1.2	3.0	3.1	0.5	436	771
<b>Total venture capital funds</b>									<b>75,893</b>	<b>100,123</b>

	Domicile	Investment currency (IC)	Number of shares as at 31.3.2011	Changes in number of shares over the last 9 months	Changes in number of shares over the last 3 months	Number of shares as at 31.12.2011	Ownership as % of portfolio company	Fair value as at 31.12.2011 (CHF 000)	Fair value as at 31.3.2011 (CHF 000)	
<b>Public companies</b>										
Basilea Pharmaceutica	P <sup>1</sup> Switzerland	CHF	665,038	1,250,192	188,851	1,915,230	20.0%	68,374	44,026	
Pacira Pharmaceuticals	P <sup>1</sup> USA	USD	3,137,597	307,692	307,692	3,445,289	13.6%	27,957	20,473	
Swedish Orphan Biovitrum	P <sup>1</sup> Sweden	SEK	1,114,000	278,500	0	1,392,500	0.5%	2,864	4,679	
SkyePharma	UK	GBP	4,976,806	0	0	4,976,806	20.8%	2,594	3,006	
China Nuokang Biopharmaceuticals	P <sup>1</sup> China	USD	355,652	0	0	355,652	1.8%	921	1,503	
Other investments								9,148	9,694	
<b>Total public companies</b>									<b>111,858</b>	<b>83,380</b>
<b>Total investments</b>									<b>405,420</b>	<b>450,953</b>

P<sup>1</sup>) The position originates from the private companies portfolio.

## Net asset value (NAV) and shares of HBM BioVentures Ltd versus market

in Swiss francs, indices indexed (12.7.2001 = 100)



## Significant shareholders

Based on the notifications received by the Company, the following shareholders are known to hold 3 percent or more of the share capital of HBM BioVentures as at 31 December 2011:

Shareholder	Latest notification of shareholding	Published on
Astellas Pharma Inc.	11.04%	7.4.2011
HBM BioVentures Ltd (treasury shares)	7.31%	31.12.2011
Alpine Select Ltd/ Daniel Sauter	5.11%	31.3.2011
BVK Personalvorsorge des Kantons Zürich	3.92%	12.2.2008

## Information on shares

Swiss security number	1.262.725
German security number	984345
ISIN	CH 0012627250
CUSIP	H 3553X112
Telekurs	126,126272
SIX Swiss Exchange Ticker	HBMN
Internet	www.hbmbioventures.com

## Board of Directors

Hans Peter Hasler, Chairman  
 Prof. Dr Dr h.c. mult. Heinz Riesenhuber<sup>1)</sup>,  
 Vice Chairman  
 Dr Eduard E. Holdener  
 Robert A. Ingram<sup>2)</sup>  
 Dr Rudolf Lanz<sup>12)</sup>  
 Dr Dr h.c. Henri B. Meier, Honorary Chairman  
 Dr Benedikt Suter, Secretary of the Board of Directors

<sup>1)</sup> Member of the Audit Committee  
<sup>2)</sup> Member of the Nominating Committee

## Management

Dr Andreas Wicki, Chief Executive Officer  
 Erwin Troxler, Chief Financial Officer

## Fees

Annual management fee:  
 1.2% of Company assets plus  
 0.3% of the Company's market capitalisation  
 High water mark per share  
 for all outstanding shares NAV of CHF 107.71

